Clearance Summary
Tina-quant Cystatin C Gen.2 received FDA 510(k) clearance under submission number K161817, sponsored by Roche Diagnostics Operations (Rdo). The device was reviewed via the Special premarket notification pathway and assigned to the Clinical Chemistry review panel. The statutory decision date of record is 2016-07-27.
- Submission: K161817
- Applicant / Sponsor: Roche Diagnostics Operations (Rdo)
- Clearance pathway: Special
- Review panel: Clinical Chemistry
- Device class: Class II
- Regulation citation: 21 CFR 862.1225
- Decision date: 2016-07-27
Classification & Regulation
This clearance is catalogued under FDA product code NDY and 21 CFR 862.1225, within the Clinical Chemistry review panel as a Class II device.